Status:
COMPLETED
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
Lead Sponsor:
Response Pharmaceuticals
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
Detailed Description
1. HbA1c after 12 weeks 2. FPG after 12 weeks 3. Safety and tolerability 4. Plasma levels of SLx-4090
Eligibility Criteria
Inclusion
- HbA1c 7-11%
- On a stable dose of metformin for at least 6 weeks
Exclusion
- Type 1 Diabetes
- Antidiabetic medication other than or in addition to metformin
- FPG \> 270 mg/dL
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00871936
Start Date
April 1 2009
End Date
October 1 2009
Last Update
November 18 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim, California, United States, 92801
2
Burbank, California, United States, 91505
3
Los Angeles, California, United States, 90036
4
Los Angeles, California, United States, 90057